Yatharth Hospital & Trauma Care Services Limited moves to reshape its capital structure

The EGM explanatory statement does not provide a separate rupee split between debt reduction and the Noida/Greater Noida expansion.

It discloses the proceeds in two broad buckets:

• Rs 2,362.50 Crores, to be used over three years for expansion and development of the hospital network and healthcare infrastructure, expenditure requirements of the company and subsidiaries, working capital, and debt repayment. The statement does not break this amount down further between debt repayment, Noida expansion, Greater Noida expansion, or working capital. ^[1]
• Rs 787.50 Crores for other general corporate purposes, also over three years. ^[1]

Accordingly, against the total proposed issue of approximately Rs 3,150 Crores, the disclosed allocation is approximately 75% to the combined expansion/infrastructure, working-capital and debt-repayment bucket and 25% to general corporate purposes. The company allows inter-se movement of up to ±10% between the stated objects, subject to applicable regulations. ^[1]

Bottom line: the EGM statement confirms a combined pool for expansion and debt repayment, but does not specify how much is earmarked for debt reduction versus the ongoing Noida and Greater Noida facility expansion.

The transaction would dilute existing holders but not alter promoter control: Rasmalai Limited would become a new public shareholder with 24.87% of the post-issue fully diluted capital, while the Tyagi promoter group would remain the largest block. The increase in authorized share capital is only an enabling step; it does not itself change the ownership pattern.

Fully diluted post-issue ownership

The proposed issue comprises up to 1,30,26,516 equity shares and 1,89,47,664 warrants, with the investor receiving 24.87% on a fully diluted basis. The authorized share capital is proposed to rise from Rs 115 Crores to Rs 150 Crores. ^[2]

Notes: † Derived by assuming proportional dilution of existing holders: existing holders retain 75.13% after the new investor receives 24.87%. Promoter holding = 55.80% × 75.13% = 41.92%; existing public holding = 44.20% × 75.13% = 33.21%. The percentages are approximate because the reported inputs are rounded.

The fully diluted outcome includes warrant conversion. At the initial allotment stage, only the equity shares are issued upfront; the warrants carry a future right to subscribe to one equity share each, so the immediate, pre-conversion ownership pattern will differ. The warrants require 25% payment upfront and the balance 75% on exercise. ^[2]

SEBI (ICDR) pricing formula

For the preferential issue, the statutory floor-price test is:

Floor price = higher of:

1. 90-trading-day VWAP of the equity shares preceding the relevant date; and 2. 10-trading-day VWAP preceding the relevant date.

The relevant date was reported as 15 September 2026. ^[3] Applying the SEBI pricing framework, the disclosed floor price was Rs 984.70 per security, while the company set the issue price for both shares and warrants at Rs 985.17 per security. ^[4]

Thus:

Issue price = Rs 985.17 = Rs 984.70 floor price + Rs 0.47 premium

The announcement reports the resulting floor price but does not provide the separate 90-day and 10-day VWAP inputs. Therefore, it is not possible to independently determine from the disclosed figures which VWAP was the binding limb of the formula.

The restructuring is directionally consistent with the IPO-era strategy—use equity to support expansion while repaying debt—but it is materially larger, broader and less project-specific. Given current leverage of only 0.14x gross debt-to-equity and 0.02x net debt-to-equity on a consolidated Q1 FY27 basis, the proposed fund raise appears primarily to pre-fund expansion and optionality rather than repair a stressed balance sheet. ^{[5] [6]}

The key continuity is that both plans avoid making expansion wholly debt-funded: debt repayment remains an eligible use, while capital expenditure and hospital-network growth remain central. The key change is scale and flexibility. The current plan permits allocation across expansion, subsidiaries, working capital and debt repayment, with inter-object variation of up to 10%; general corporate-purpose funds cannot be shifted into the other objects. ^[1]

One important limitation is that the restructuring remains a proposed transaction subject to shareholder and other regulatory approvals, rather than a completed capital infusion. ^[8] Accordingly, the cleanest conclusion is: the exercise is compatible with the RHP’s conservative, equity-supported expansion model, but it represents a transition from targeted IPO deployment to a much larger pre-funded growth platform, with dilution and execution of the expanded investment programme becoming the main issues rather than leverage reduction alone.